HighPoint Advisor Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

HighPoint Advisor Group’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$22K	Buy	+10,242	New	+$22.3K	﹤0.01%	523
2021 Q3	$50K	Sell	10,277 -4,402	-30%	-$24.3K	﹤0.01%	545
2021 Q2	$100K	Sell	14,679 -600	-4%	-$4.85K	0.01%	525
2021 Q1	$122K	Hold	15,279	–	–	0.01%	479
2020 Q4	$122K	Buy	15,279 +110	+0.7%	+$647	0.01%	454
2020 Q3	$76K	Hold	15,169	–	–	0.01%	378
2020 Q2	$78K	Hold	15,169	–	–	0.02%	342
2020 Q1	$66K	Buy	15,169 +397	+3%	+$1.47K	0.02%	331
2019 Q4	$53K	Hold	14,772	–	–	0.01%	362
2019 Q3	$60K	Buy	14,772 +4,639	+46%	+$18.6K	0.01%	478
2019 Q2	$34K	Buy	+10,133	New	+$48.2K	0.01%	482

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

HighPoint Advisor Group's PRTK Position: Q2 2022 in Review

HighPoint Advisor Group opened a new position in Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022: 10,242 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #523 among its holdings. This is a return to the name: HighPoint Advisor Group previously reported a position in PRTK as recently as Q3 2021.

HighPoint Advisor Group first reported a position in PRTK in Q2 2019 and has held it in 11 quarters since. The position peaked at $122K in Q1 2021. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

HighPoint Advisor Group held 10,242 shares of Paratek Pharmaceuticals, Inc. worth $22K as of Q2 2022.
Paratek Pharmaceuticals, Inc. was a new HighPoint Advisor Group position in Q2 2022.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of HighPoint Advisor Group's portfolio in Q2 2022, its #523 holding.
HighPoint Advisor Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2019 and has held it in 11 quarters since.
HighPoint Advisor Group's Paratek Pharmaceuticals, Inc. position peaked at $122K in Q1 2021.
84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on HighPoint Advisor Group's 13F filing for Q2 2022, filed 15 Aug 2022.